# Isabel Fox

> Isabel Fox is a seed investor at Hoxton Ventures (London) backing Software and Life Science. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Hoxton Ventures](https://shizune.co/investors/profile/hoxton-ventures)
- Location: London, United Kingdom
- Total investments: 6
- Last investment: Mar 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/isabelfox
- Website: https://x.com/ifox916
- Facebook: https://www.facebook.com/isabel.fox.988

Isabel Fox is a seed investor at Hoxton Ventures in London focused on Software and Life Science. Isabel Fox is based out of London, England, and is the Head of IR of Hoxton Ventures. Isabel previously worked at Molten Ventures as a Head Third Party Funds. Isabel Fox attended the University of Exeter. Isabel Fox has been certified as a Integrative Nutrition Health Coach (INHC).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 33% |
| Life Science | 2 | 33% |
| Biotechnology | 2 | 33% |
| Funerals | 1 | 17% |
| Health Care | 1 | 17% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 17% |
| Pre-Seed | 1 | 17% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Funding Round | 1 | 17% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Treos Bio | Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients. | $16.4M | Convertible Note | Mar 31, 2021 |  |
| Synthace | Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all oftheir experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible. | $25.6M | Series B | Dec 12, 2018 |  |
| Synthace | Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all oftheir experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible. | $9.3M | Series A | Sep 19, 2017 |  |
| Beyond | Your knowledgeable companion for everything after life. Whatever journey you’re on, you can trust Beyond to help you make the best decision. | $955K | Pre-Seed | Oct 11, 2016 |  |
| Beyond | Your knowledgeable companion for everything after life. Whatever journey you’re on, you can trust Beyond to help you make the best decision. | $2.5M | Seed |  |  |
| Sparrho | Sparrho is a world leader in making science accessible to build trust in brands. They achieve this using their unique combination of AI and PhD experts, which they call Augmented Intelligence.Sparrho was founded in 2013 out of frustration with existing literature search tools by two Oxbridge scientists, and now has a growing and tightly knit teambased in London, UK.Today Sparrho caters to Fortune 500 companies across the globe. Their platform uses augmented intelligence to aggregate, curate and summarise the latest in scientific research. | $3M |  |  |  |

6 of 6 investments shown.

## Co-investors
- [11.2 Capital](https://shizune.co/investors/profile/112capital) — VC Fund, 1 deal together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 1 deal together
- [Planetary Technologies](https://shizune.co/investors/profile/bioeconomy-capital) — VC Fund, 1 deal together
- [Horizons Ventures](https://shizune.co/investors/profile/horizons-ventures) — VC Fund, 1 deal together
- [UK Innovation & Science Seed Fund](https://shizune.co/investors/profile/rainbow-seed-fund) — VC Fund, 1 deal together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 1 deal together

## About Hoxton Ventures

VC Fund · London, United Kingdom

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

5 contacts available at Hoxton Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Hussein Kanji | Partner | https://shizune.co/investors/profile/hussein-kanji |
| Bryan Gartner | Partner | https://shizune.co/investors/profile/bryan-gartner |
| Dahlia Jacobs | Finance Director | https://shizune.co/investors/profile/dahlia-jacobs |
| Isabel Fox | Head of IR | https://shizune.co/investors/profile/isabel-fox |
| Mandeep Singh | Venture Partner | https://shizune.co/investors/profile/mandeep-singh |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Isabel Fox invest in?

Isabel Fox invests primarily in Software, Life Science and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Isabel Fox last invest?

The most recent investment recorded for Isabel Fox closed in Mar 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co